RefleXion raises $80M for biology-guided radiotherapy tech

RefleXion Medical announced that it closed an $80 million equity financing to support its therapeutic oncology technology.

Hayward, California-based RefleXion develops biology-guided radiotherapy (BgRT) for all stages of cancer. The company designed BgRT to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors.

BgRT recently received FDA breakthrough device designation for use in lung tumors, according to a news release. RefleXion plans to scale BgRT to treat all visible cancer sites, creating a new treatment option for patients with metastatic disease.

New investors joining the $80 million round were Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

Those new investors joined existing investors TPG’s The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridg…

Read more
  • March 11, 2022
  • 0

RefleXion, Merck team up on late-stage cancer study

RefleXion announced today that it entered into a clinical collaboration with Merck to evaluate Merck’s (NYSE:MRK) Keytruda anti-PD-1 therapy in clinical trials.

Hayward, Calif.-based therapeutic oncology company RefleXion is joining forces with Merck to evaluate Keytruda’s safety and efficacy in combination with RefleXion’s biology-guided radiotherapy (BgRT) in multiple late-stage cancers, including non-small cell lung cancer, in two randomized controlled clinical trials.

The companies set their aim to establish whether treating multiple tumors with BgRT is safe and amplifies Keytruda’s therapeutic effect, according to a news release.

RefleXion’s X1 machine uses BgRT to deliver radiotherapy to multiple sites during the same treatment sessions, even for certain sites that move due to breathing or digestion. The company recently raised $100 million in a financing round following FDA clearance wins for its stereotactic body rad…

Read more
  • May 28, 2020
  • 0